JP2010513434A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513434A5
JP2010513434A5 JP2009542194A JP2009542194A JP2010513434A5 JP 2010513434 A5 JP2010513434 A5 JP 2010513434A5 JP 2009542194 A JP2009542194 A JP 2009542194A JP 2009542194 A JP2009542194 A JP 2009542194A JP 2010513434 A5 JP2010513434 A5 JP 2010513434A5
Authority
JP
Japan
Prior art keywords
oxy
azoniabicyclo
octane
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009542194A
Other languages
English (en)
Japanese (ja)
Other versions
JP4604129B2 (ja
JP2010513434A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2007/004817 external-priority patent/WO2008075005A1/en
Publication of JP2010513434A publication Critical patent/JP2010513434A/ja
Publication of JP2010513434A5 publication Critical patent/JP2010513434A5/ja
Application granted granted Critical
Publication of JP4604129B2 publication Critical patent/JP4604129B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009542194A 2006-12-19 2007-12-17 ムスカリン受容体アンタゴニストとしてのキヌクリジノール誘導体 Expired - Fee Related JP4604129B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87063806P 2006-12-19 2006-12-19
PCT/GB2007/004817 WO2008075005A1 (en) 2006-12-19 2007-12-17 Quinuclidinol derivatives as muscarinic receptor antagonists

Publications (3)

Publication Number Publication Date
JP2010513434A JP2010513434A (ja) 2010-04-30
JP2010513434A5 true JP2010513434A5 (enExample) 2010-06-17
JP4604129B2 JP4604129B2 (ja) 2010-12-22

Family

ID=39166793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009542194A Expired - Fee Related JP4604129B2 (ja) 2006-12-19 2007-12-17 ムスカリン受容体アンタゴニストとしてのキヌクリジノール誘導体

Country Status (22)

Country Link
US (1) US20100113510A1 (enExample)
EP (1) EP2121137B1 (enExample)
JP (1) JP4604129B2 (enExample)
KR (1) KR20090094460A (enExample)
CN (1) CN101610813A (enExample)
AR (1) AR064414A1 (enExample)
AT (1) ATE555111T1 (enExample)
AU (1) AU2007336054A1 (enExample)
BR (1) BRPI0721039A2 (enExample)
CA (1) CA2672446A1 (enExample)
CL (1) CL2007003690A1 (enExample)
CO (1) CO6180439A2 (enExample)
EC (1) ECSP099394A (enExample)
ES (1) ES2385681T3 (enExample)
IL (1) IL199015A0 (enExample)
MX (1) MX2009006018A (enExample)
NO (1) NO20092689L (enExample)
PE (1) PE20081837A1 (enExample)
RU (1) RU2009120229A (enExample)
TW (1) TW200831507A (enExample)
UY (1) UY30803A1 (enExample)
WO (1) WO2008075005A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
NZ589091A (en) 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
WO2009153536A1 (en) * 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
WO2010008341A1 (en) * 2008-07-16 2010-01-21 Astrazeneca Ab A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
EP2206712A1 (en) * 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
WO2010144043A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab A novel 4-methylbenzenesulphonate salt and a process for preparing a pharmaceutical composition comprising the salt
JP2013500962A (ja) 2009-07-31 2013-01-10 カディラ ヘルスケア リミティド グルココルチコイド受容体のモジュレーターとしての新規化合物
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
ES2545812T3 (es) * 2010-06-22 2015-09-16 Chiesi Farmaceutici S.P.A. Derivados aminoéster de alcaloides y composición medicinal de estos
CN102947299B (zh) * 2010-06-22 2015-07-15 奇斯药制品公司 生物碱氨基酯衍生物及其药物组合物
WO2013098145A1 (en) 2011-12-30 2013-07-04 Chiesi Farmaceutici S.P.A. Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof
CN105431432B (zh) * 2013-07-13 2018-01-09 北京硕佰医药科技有限责任公司 奎宁类化合物、其光学异构体及其制备方法和医药用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
ES2302938T3 (es) 2002-10-11 2008-08-01 Pfizer Inc. Derivados de indol como agonistas beta-2.
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
CN100445281C (zh) * 2003-05-02 2008-12-24 诺瓦提斯公司 与毒蕈碱性m3受体结合的奎宁环衍生物
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
AU2004285592B2 (en) 2003-11-03 2010-02-18 Norton Healthcare, Ltd. Soft steroid compositions for use in dry powder inhalers
CA2584413A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
TW200722418A (en) * 2005-04-20 2007-06-16 Astrazeneca Ab Novel compounds

Similar Documents

Publication Publication Date Title
JP7398391B2 (ja) N-[4-オキソ-2,3-ジヒドロ-1,5-ベンズオキサゼピン-3-イル]-5,6-ジヒドロ-4H-ピロロ[1,2-b]ピラゾール-2-カルボキサミド誘導体及び例えば過敏性腸症候群(IBS)を処置するためのRIP1キナーゼ阻害剤としての関連化合物
RU2746129C2 (ru) Биарильные монобактамные соединения и способы их применения для лечения бактериальных инфекций
JP2005533826A5 (enExample)
JP4505227B2 (ja) 1−アルキル−1−アゾニアビシクロ[2.2.2]オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
RU2009120229A (ru) Производные хинуклидинола в качестве антагонистов мускариновых рецепторов
US7718670B2 (en) Quinuclidine amide derivatives
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
JP4853918B2 (ja) グリシン輸送阻害剤としての三環式化合物の使用
RU2399620C2 (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
JP6505023B2 (ja) Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
TWI629276B (zh) 咪唑并嗒化合物
JP2008509187A5 (enExample)
JP7367038B2 (ja) Lpa1受容体のイメージングのための放射性リガンド
WO2015196071A9 (en) Compounds, compositions and methods of increasing cftr activity
JP2008500988A5 (enExample)
CN1152870A (zh) 杂环化合物作为多巴胺d3配位体的用途
JP2010509391A5 (enExample)
CN102838546A (zh) 作为5-ht2a 血清素受体调节剂用于治疗与其相关病症的吡唑衍生物
HU228594B1 (en) Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same
CA2401502A1 (en) Carboxylic acid derivatives as ip antagonists
WO2016115090A1 (en) Compounds, compositions and methods for increasing cftr activity
JP5552121B2 (ja) ロイコトリエン産生のインドリジン阻害剤
AU2013358591A1 (en) Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors
JP2010535858A5 (enExample)